S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARSCoV-2

The coronavirus disease (COVID-19) pandemic has highlighted the ability of scientists to quickly react to the immense challenge presented to the world. The orally available 3CL protease inhibitor S-217622 is currently progressing through clinical trials and its discovery via structure-based drug design, screening and optimization by Shionogi and Hokkaido University is presented here.

Automated summary

The COVID-19 pandemic has highlighted scientists' ability to respond quickly to global challenges. This article presents the discovery of the orally available 3CL protease inhibitor S-217622 through structure-based drug design, screening, and optimization by Shionogi and Hokkaido University.